Transaction Information
Evaxion Biotech A/S (NASDAQ: EVAX) announced the closing of its initial public offering of 3,000,000 American Depositary Shares ("ADSs") at a public offering price of $10.00 per ADS. The gross proceeds from the offering, before deducting underwriting fees and commissions and other offering expenses, were $30 million. The shares began trading on the Nasdaq Capital Market on February 5, 2021 under the ticker symbol "EVAX".
Evaxion has granted the underwriters an option for a period of 30 days from the date of the final prospectus to purchase an additional 450,000 ADSs at the initial public offering price.
Ladenburg Thalmann & Co. Inc. acted as lead manager in connection with the offering.
About Evaxion
Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. For more information visit www.evaxion-biotech.com
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.